We are live on ! Find out more
NBSE

NeuBase Therapeutics, Inc. Common Stock
NBSE

Delisted

NBSE was delisted on the 10th of May, 2024.

Back to rankings

1 hedge funds and large institutions have $0 invested in NeuBase Therapeutics, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, 0 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% less funds holding

Funds holding: 3 → 1 (-2)

100% less capital invested

Capital invested by funds: $4.95K → $0 (-$4.95K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 2

Holders
1
Holders Change
-2
Holders Change %
-66.67%
% of All Funds
0.01%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
–
Reduced
–
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

No buyers this quarter

Top Sellers

Rank Fund Capital Flow
1
BBA
Baader Bank Aktiengesellschaft
Germany
-$4.95K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baader Bank Aktiengesellschaft
Germany
– -$4.95K -16,089 Closed

NBSE Hedge Fund Activity: Q3 2024 in Review

1 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in NeuBase Therapeutics, Inc. Common Stock (NBSE) for Q3 2024, worth a combined $0 — down 100% from $4.95K a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of NBSE and 0 opened new positions — a net loss of 2 holders — while 0 trimmed existing stakes and 0 added.

The largest seller was Baader Bank Aktiengesellschaft, exiting entirely with an estimated $4.95K sold.

  • 1 institutional investor held NeuBase Therapeutics, Inc. Common Stock (NBSE) as of Q3 2024, down from 3 in Q2 2024.
  • Funds reported $0 of NeuBase Therapeutics, Inc. Common Stock stock for Q3 2024, down 100% quarter-over-quarter.
  • 0 funds opened new NeuBase Therapeutics, Inc. Common Stock positions in Q3 2024 and 2 closed out, a net change of -2 holders.
  • The largest NeuBase Therapeutics, Inc. Common Stock seller in Q3 2024 was Baader Bank Aktiengesellschaft, an estimated $4.95K sold.

Based on aggregated 13F filings for Q3 2024.